-- Scott Roberts
FRIDAY, Jan. 31, 2014 (HealthDay News) -- Hetlioz (tasimelteon)
has been approved by the U.S. Food and Drug Administration to treat
a sleep condition caused by a completely blind person's inability
to regulate the body clock by recognizing light from dark.
The condition is called non-24-hour sleep wake disorder.
Affected people may have difficulty falling asleep or staying
asleep, and may become groggy, the agency said Friday in announcing
Up to 100,000 people in the United States have the disorder, the
FDA said in a news release.
The safety and effectiveness of the new drug were evaluated in a
clinical study of 104 completely blind people. Reported side
effects included headache, elevated liver enzymes, unusual dreams
and infections of the upper respiratory or urinary tract.
The drug is produced by Vanda Pharmaceuticals, based in
FDAto learn more.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.